HepQuant Names Pharma Veteran Timothy Hermes Vice President of Market Access
DENVER (Sep. 24th, 2021) — HepQuant, LLC, a Denver, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced that Timothy Hermes has joined the company as Vice President of Market Access. Mr. Hermes will leverage his more than 30 years experience in the pharmaceutical industry to lead HepQuant’s market access strategy, including government relations and exploration of payer and reimbursement opportunities.
“Adding Tim to the HepQuant team brings stronger focus to market access options as we execute on our vision of delivering innovative, noninvasive tests of liver function to patients, investigators, care providers, and payers,” noted Dr. Gregory T. Everson, CEO & Chief Medical Officer at HepQuant.
“HepQuant is in a unique position to provide a comprehensive picture of liver health in a cost-effective and non-invasive way to its target audiences and I am excited to apply my extensive patient access experience on behalf of this mission,” said Mr. Hermes.
Mr. Hermes has worked on a variety of complex coverage and reimbursement issues in the past, most notably changing a Medicare Least Costly Alternative coverage policy that was keeping seniors with Chronic Obstructive Pulmonary Disease from accessing an important new drug.
More recently, Mr. Hermes served as Vice President of Market Access at Aurinia Pharmaceuticals where he created and implemented the market access launch plan for voclosporin, the first FDA-approved oral therapy for lupus nephritis (LN). In this role he was responsible for conducting the pricing studies, building the economic models, and devising the overall strategy to optimize payer coverage. LN is a condition that causes irreversible kidney damage and increases the risk of kidney failure.
Prior to Aurinia, Mr. Hermes served in a similar leadership position for Ablynx, now Sanofi-Genzyme, where he built and implemented a payer reimbursement and coverage strategy that maximized both across the payer and hospital inpatient landscapes for caplacizumab, a biologic indicated for acquired thrombotic thrombocytopenic purpura, a potentially fatal blood disease. In addition to similar past positions in government affairs and market access within the pharmaceutical industry, Mr. Hermes also spent three years as a market access consultant to the pharma industry specializing in Medicare coding, coverage, and payment for a variety of products, including drug-device combination products. He holds a Bachelor of Sciences degree from Centenary College in Shreveport, LA.
Headquartered in Denver, Colorado, HepQuant, LLC, is a privately-held diagnostics company. HepQuant’s products are investigational combination drug and in-vitro diagnostic devices and have not yet been evaluated or reviewed by the US Food and Drug Administration (FDA) for commercial sale. They are currently available for investigational use via the FDA guidelines for investigational device exemptions (IDEs). For additional information, visit www.hepquant.com.
For further inquiries: Bradley C. Everson | Chief Business Development Officer
Ph: (303) 923-2150 | [email protected]
Download Press Release PDF